Review
Open access
Aug 2026
CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities
Ongoing studies evaluating CDK2 inhibitors, CDK4-selective agents, immunotherapy combinations, and circulating tumor DNA (ctDNA)-guided strategies aim to further refine treatment sequencing and improve long-term outcomes in HR+/HER2- breast cancer.
Luise Chinea, C. Hauer, Khushboo Pal et al.
· Targeted oncology · 0 citations